Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management

Overview

Journal J Allergy Clin Immunol Pract

Specialty Allergy & Immunology

Date 2018 Sep 12

PMID 30201096

Citations 19

Authors

Erin C Steinbach

Michelle Hernandez

Evan S Dellon

Affiliations

Soon will be listed here.

Abstract

The eosinophilic gastrointestinal diseases (EGIDs) represent disorders of the gastrointestinal (GI) tract that result from the local infiltration and aberrant activity of eosinophils and other immune cells. Eosinophilic esophagitis (EoE) is the most well-characterized EGID and is defined by the presence of intraepithelial eosinophils in the esophagus (≥15 eosinophils per high-powered field) and clinical symptoms associated with esophageal dysfunction. The other EGIDs are rare and lack strong data regarding pathogenesis and management. The incidence and prevalence of EoE are increasing, and EoE is now a major cause of upper GI morbidity. Management is multidisciplinary, with collaboration between gastroenterologists, allergists, pathologists, and dieticians, and is aimed at amelioration of symptoms and prevention of long-term complications such as esophageal stricture. Treatment options for EoE include proton pump inhibitors, swallowed topical corticosteroids, and elimination diets. Esophageal dilation is used when esophageal strictures or fibrostenotic changes are present. Additional therapies targeting eosinophils and other mediators of Th2 inflammation are under development and are promising. Treatment options for other EGIDs typically involve corticosteroids or dietary elimination.

Citing Articles

Detection of Eosinophilic Cell-free Granules Based on Expression of CCR3 and MBP Markers in Esophageal Biopsy Specimens of Patients with Suspected and Confirmed Eosinophilic Esophagitis.

Ebrahimi S, Khatami S, Mahjoub F, Monajemzadeh M, Yousefi A, Hosseini A Pediatr Gastroenterol Hepatol Nutr. 2025; 28(1):19-26.

PMID: 39839467 PMC: 11745569. DOI: 10.5223/pghn.2025.28.1.19.

Disease Burden and Spectrum of Symptoms that Impact Quality of Life in Pediatric Patients with Eosinophilic Esophagitis.

Chehade M, Hiremath G, Zevit N, Oliva S, Pela T, Khodzhayev A Gastro Hep Adv. 2024; 3(8):1054-1068.

PMID: 39529644 PMC: 11550740. DOI: 10.1016/j.gastha.2024.08.009.

Effects of proton pump inhibitors on inflammatory bowel disease: An updated review.

Liang Y, Meng Z, Ding X, Jiang M World J Gastroenterol. 2024; 30(21):2751-2762.

PMID: 38899331 PMC: 11185295. DOI: 10.3748/wjg.v30.i21.2751.

Duodenal stenosis, an unusual presentation of eosinophilic gastroenteritis: a case report.

Di Mari C, Pozzi E, Mantegazza C, Destro F, Meroni M, Coletta M Front Pediatr. 2024; 12:1390946.

PMID: 38699150 PMC: 11063303. DOI: 10.3389/fped.2024.1390946.

The Dual Lens of Endoscopy and Histology in the Diagnosis and Management of Eosinophilic Gastrointestinal Disorders-A Comprehensive Review.

Barchi A, Vespa E, Passaretti S, DellAnna G, Fasulo E, Yacoub M Diagnostics (Basel). 2024; 14(8).

PMID: 38667503 PMC: 11049211. DOI: 10.3390/diagnostics14080858.

References

Moawad F, Veerappan G, Dias J, Baker T, Maydonovitch C, Wong R . Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol. 2013; 108(3):366-72. DOI: 10.1038/ajg.2012.443. View

Wen T, Dellon E, Moawad F, Furuta G, Aceves S, Rothenberg M . Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol. 2014; 135(1):187-97. PMC: 4289084. DOI: 10.1016/j.jaci.2014.08.043. View

Katz Y, Rajuan N, Goldberg M, Eisenberg E, Heyman E, Cohen A . Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy. J Allergy Clin Immunol. 2010; 126(1):77-82.e1. DOI: 10.1016/j.jaci.2010.04.020. View

Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos J, Fernandez-Bermejo M . Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 2010; 9(2):110-7. DOI: 10.1016/j.cgh.2010.09.019. View

Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M . A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2015; 65(3):390-9. PMC: 4789829. DOI: 10.1136/gutjnl-2014-308815. View

Korsapati H, Babaei A, Bhargava V, Dohil R, Quin A, Mittal R . Dysfunction of the longitudinal muscles of the oesophagus in eosinophilic oesophagitis. Gut. 2009; 58(8):1056-62. DOI: 10.1136/gut.2008.168146. View

Moawad F, Cheatham J, DeZee K . Meta-analysis: the safety and efficacy of dilation in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2013; 38(7):713-20. DOI: 10.1111/apt.12438. View

Philpott H, Nandurkar S, Royce S, Thien F, Gibson P . Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016; 44(3):223-33. DOI: 10.1111/apt.13676. View

Lucendo A, Arias A, Gonzalez-Cervera J, Olalla J, Molina-Infante J . Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2015; 137(3):931-4.e2. DOI: 10.1016/j.jaci.2015.07.033. View

10.

Rothenberg M . Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004; 113(1):11-28. DOI: 10.1016/j.jaci.2003.10.047. View

11.

Franciosi J, Hommel K, DeBrosse C, Greenberg A, Greenler A, Abonia J . Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011; 11:126. PMC: 3228698. DOI: 10.1186/1471-230X-11-126. View

12.

Jensen E, Shah N, Hoffman K, Sonnenberg A, Genta R, Dellon E . Seasonal variation in detection of oesophageal eosinophilia and eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015; 42(4):461-9. PMC: 4506219. DOI: 10.1111/apt.13273. View

13.

Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C . Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011; 9(5):400-9.e1. DOI: 10.1016/j.cgh.2011.01.017. View

14.

Marietta E, Geno D, Smyrk T, Becker A, Alexander J, Camilleri M . Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016; 45(3):427-433. PMC: 6944330. DOI: 10.1111/apt.13877. View

15.

Haas A, Maune N . Clinical presentation of feeding dysfunction in children with eosinophilic gastrointestinal disease. Immunol Allergy Clin North Am. 2009; 29(1):65-75, ix. DOI: 10.1016/j.iac.2008.09.014. View

16.

Pasman E, Heifert T, Nylund C . Esophageal squamous papillomas with focal dermal hypoplasia and eosinophilic esophagitis. World J Gastroenterol. 2017; 23(12):2246-2250. PMC: 5374137. DOI: 10.3748/wjg.v23.i12.2246. View

17.

Lucendo A, Molina-Infante J, Arias A, von Arnim U, Bredenoord A, Bussmann C . Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3):335-358. PMC: 5415218. DOI: 10.1177/2050640616689525. View

18.

Rassbach W, Rubenstein J, Elkins M, DeMatos V, Greenson J, Greenhawt M . Age-based differences in the diagnosis and management of esophageal eosinophilia. J Allergy Clin Immunol Pract. 2015; 3(1):81-87.e1. PMC: 7423520. DOI: 10.1016/j.jaip.2014.06.019. View

19.

Philpott H, Dellon E . The role of maintenance therapy in eosinophilic esophagitis: who, why, and how?. J Gastroenterol. 2017; 53(2):165-171. PMC: 5794528. DOI: 10.1007/s00535-017-1397-z. View

20.

Croese J, Fairley S, Masson J, Chong A, Whitaker D, Kanowski P . Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc. 2003; 58(4):516-22. DOI: 10.1067/s0016-5107(03)01870-4. View